These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 36399266)
21. Pathological changes within the cerebral vasculature in Alzheimer's disease: New perspectives. Fisher RA; Miners JS; Love S Brain Pathol; 2022 Nov; 32(6):e13061. PubMed ID: 35289012 [TBL] [Abstract][Full Text] [Related]
22. Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease. Deane R; Zlokovic BV Curr Alzheimer Res; 2007 Apr; 4(2):191-7. PubMed ID: 17430246 [TBL] [Abstract][Full Text] [Related]
26. Interactions of β-amyloid peptide with fibrinogen and coagulation factor XII may contribute to Alzheimer's disease. Ahn HJ; Chen ZL; Zamolodchikov D; Norris EH; Strickland S Curr Opin Hematol; 2017 Sep; 24(5):427-431. PubMed ID: 28661939 [TBL] [Abstract][Full Text] [Related]
27. Alzheimer's disease peptide beta-amyloid interacts with fibrinogen and induces its oligomerization. Ahn HJ; Zamolodchikov D; Cortes-Canteli M; Norris EH; Glickman JF; Strickland S Proc Natl Acad Sci U S A; 2010 Dec; 107(50):21812-7. PubMed ID: 21098282 [TBL] [Abstract][Full Text] [Related]
28. Label-free vibrational imaging of different Aβ plaque types in Alzheimer's disease reveals sequential events in plaque development. Röhr D; Boon BDC; Schuler M; Kremer K; Hoozemans JJM; Bouwman FH; El-Mashtoly SF; Nabers A; Großerueschkamp F; Rozemuller AJM; Gerwert K Acta Neuropathol Commun; 2020 Dec; 8(1):222. PubMed ID: 33308303 [TBL] [Abstract][Full Text] [Related]
29. Differing associations between Aβ accumulation, hypoperfusion, blood-brain barrier dysfunction and loss of PDGFRB pericyte marker in the precuneus and parietal white matter in Alzheimer's disease. Miners JS; Schulz I; Love S J Cereb Blood Flow Metab; 2018 Jan; 38(1):103-115. PubMed ID: 28151041 [TBL] [Abstract][Full Text] [Related]
30. Fibrinogen and beta-amyloid association alters thrombosis and fibrinolysis: a possible contributing factor to Alzheimer's disease. Cortes-Canteli M; Paul J; Norris EH; Bronstein R; Ahn HJ; Zamolodchikov D; Bhuvanendran S; Fenz KM; Strickland S Neuron; 2010 Jun; 66(5):695-709. PubMed ID: 20547128 [TBL] [Abstract][Full Text] [Related]
31. Reversing pathology in a preclinical model of Alzheimer's disease by hacking cerebrovascular neoangiogenesis with advanced cancer therapeutics. Singh CSB; Choi KB; Munro L; Wang HY; Pfeifer CG; Jefferies WA EBioMedicine; 2021 Sep; 71():103503. PubMed ID: 34534764 [TBL] [Abstract][Full Text] [Related]
32. Blood-Brain Barrier Dysfunction and the Pathogenesis of Alzheimer's Disease. Yamazaki Y; Kanekiyo T Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28902142 [TBL] [Abstract][Full Text] [Related]
33. Cerebral amyloid angiopathy-linked β-amyloid mutations promote cerebral fibrin deposits via increased binding affinity for fibrinogen. Cajamarca SA; Norris EH; van der Weerd L; Strickland S; Ahn HJ Proc Natl Acad Sci U S A; 2020 Jun; 117(25):14482-14492. PubMed ID: 32518112 [TBL] [Abstract][Full Text] [Related]
35. β-Amyloid, cholinergic transmission, and cerebrovascular system -- a developmental study in a mouse model of Alzheimer's disease. Kuznetsova E; Schliebs R Curr Pharm Des; 2013; 19(38):6749-65. PubMed ID: 23530514 [TBL] [Abstract][Full Text] [Related]
36. Mediators of cerebral hypoperfusion and blood-brain barrier leakiness in Alzheimer's disease, vascular dementia and mixed dementia. Tayler H; Miners JS; Güzel Ö; MacLachlan R; Love S Brain Pathol; 2021 Jul; 31(4):e12935. PubMed ID: 33410232 [TBL] [Abstract][Full Text] [Related]